High-grade serous ovarian cancer (HGSOC) patients with defects in HRR are highly sensitive to PARP inhibition despite the fact that TP53 mutations are detected in 96% of HGSOC tumors80. This evidence concerns the gene PARP1 and ovarian serous adenocarcinoma.